ゲルムラインのCDH1変種と生涯がんリスク

Carrie E Ryan¹, Grace-Ann Fasaye², Amber F Gallanis¹

¹Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

JAMA

|June 14, 2024

まとめ

CDH1遺伝子変異を持つ人は,これまで考えられていたより,胃がんの生涯リスクが低い (7%~10%). しかし,女性で乳がんになるリスクは依然として 37%です.

科学分野:

遺伝学とゲノミクス
腫瘍学
ガン流行病学

背景:

遺伝的な拡散性胃がんと乳がんは,しばしばCDH1遺伝子変異と関連しています.
前回のCDH1変異媒介者のリスク評価は高く,臨床管理に影響を与えた.
遺伝子カウンセリングや予防戦略にはリスクの正確な評価が不可欠です

研究の目的:

CDH1の病原性または病原性可能性が高い (P/LP) 変種を有する個体における胃がんおよび乳がんリスクの最新推定を提供すること.
北米のコホートに基づいて生涯累積リスクを再評価する.
遺伝性がん症候群の管理のための臨床ガイドラインを参考にすること.

主な方法:

北米の213世帯を対象とした多センター,遡及的なコホートとモデリング研究です.
CDH1P/LPの変種を持つ883人を含む7323人のデータを分析した.
80歳までの累積リスクの推定とHR

主要な成果:

胃がんの生涯累積リスクは,以前の推定値より7%~10%でした.
乳がんの生涯累積リスクは女性で36. 8%であり,以前の研究結果と一致していた.
患者に胃がんと乳がんの両方のリスクが著しく高まっていることが示された.

結論:

ゲルムラインのCDH1 P/ LP変異は,胃癌と乳癌の重大なリスクと関連しています.
最新のリスク推定では,胃がんのリスクは低いが,女性で乳がんのリスクは高いことが示唆されている.
これらの発見は,CDH1変異を有する個体に対する管理戦略と遺伝子カウンセリングの改善に不可欠です.

さらに関連する動画

08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.7K

09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.2K

関連する概念動画

02:59

Cancer Prevention

6.1K

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

6.1K

02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.9K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Genetic Lingo

Mutagenicity and Carcinogenicity

1.2K

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

1.2K

01:20

Mismatch Repair

4.8K

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

4.8K

01:35

Pedigree Analysis

84.2K